Dupixent® insurance, approved

Claimable can help you get the coverage you need.
Evidence-backed appeals tailored to your unique situation.
Any condition, covered
We appeal for all FDA-approved Dupixent indications.
✓ Atopic dermatitis
✓ Asthma
✓ Rhinosinusitis
✓ Eosinophilic esophagitis
✓ Prurigo nodularis
✓ Bullous pemphigoid

How it works




Designed to fight Dupixent® switches
///////////////////////////////////////////////////////////////////////
//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////
I’ve been managing atopic dermatitis for years, and while I’ve tried a range of topical treatments, they haven’t been enough to control my symptoms. I regularly deal with patches of inflamed, itchy skin that make it hard to focus during the day and often interrupt my sleep at night.
It’s exhausting to have to plan around flare-ups — I avoid certain fabrics, outdoor activities, or even social plans if I know my skin is acting up. It’s not always visible to others, but it’s something I have to manage constantly, and it affects my quality of life extensively.
///////////////////////////////////////////////////////////////////////
//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////

///////////////////////////////////////////////////////////////////////
//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////
A systematic review of Phase 3 trials reports that dupilumab “provides rapid improvements (in as little as 1 week) and sustained efficacy (up to 4 years) … not only improves skin signs and symptoms, but also provides multiple health benefits beyond the skin, including improvements in quality of life, itch, sleep disturbances, and pain/discomfort.
///////////////////////////////////////////////////////////////////////
//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////

///////////////////////////////////////////////////////////////////////
//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////
Under New York law, a health plan that provides essential health benefits may not implement mid‑year formulary changes, such as removing a drug from the formulary or moving it to a higher cost‑sharing tier, without triggering legal protections.
In particular, Senate Bill S4111 (2021‑2022 session) added § 4909 to the New York Insurance Law and related amendments to the New York Public Health Law, which prohibits a plan from removing a prescription drug from its formulary or shifting it to a tier with greater cost–sharing during a contract year, unless certain exceptions apply.
///////////////////////////////////////////////////////////////////////
//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////


Why appeal with Claimable?
From start to send in minutes

Let’s get you covered.

Here's an example of an FAQ
Here's an example of an FAQ
Here's an example of an FAQ
Here's an example of an FAQ
Here's an example of an FAQ
Here's an example of an FAQ
Here's an example of an FAQ

